TR199903057T2 - Diabetin tiazolidinedion ve metformin ile tedavisi. - Google Patents

Diabetin tiazolidinedion ve metformin ile tedavisi.

Info

Publication number
TR199903057T2
TR199903057T2 TR1999/03057T TR9903057T TR199903057T2 TR 199903057 T2 TR199903057 T2 TR 199903057T2 TR 1999/03057 T TR1999/03057 T TR 1999/03057T TR 9903057 T TR9903057 T TR 9903057T TR 199903057 T2 TR199903057 T2 TR 199903057T2
Authority
TR
Turkey
Prior art keywords
treatment
diabetes
thiazolidinedione
metformin
diabetes mellitus
Prior art date
Application number
TR1999/03057T
Other languages
English (en)
Turkish (tr)
Inventor
Alistair Smith Stephen
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26311745&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR199903057(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9712857.3A external-priority patent/GB9712857D0/en
Priority claimed from GBGB9806706.9A external-priority patent/GB9806706D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of TR199903057T2 publication Critical patent/TR199903057T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
TR1999/03057T 1997-06-18 1998-06-15 Diabetin tiazolidinedion ve metformin ile tedavisi. TR199903057T2 (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9712857.3A GB9712857D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806706.9A GB9806706D0 (en) 1998-03-27 1998-03-27 Novel method

Publications (1)

Publication Number Publication Date
TR199903057T2 true TR199903057T2 (xx) 2000-04-21

Family

ID=26311745

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/03057T TR199903057T2 (xx) 1997-06-18 1998-06-15 Diabetin tiazolidinedion ve metformin ile tedavisi.

Country Status (38)

Country Link
US (3) US20060100247A1 (en:Method)
EP (2) EP1787646A3 (en:Method)
JP (1) JP2002504137A (en:Method)
KR (2) KR20060105005A (en:Method)
CN (2) CN1114404C (en:Method)
AP (1) AP1279A (en:Method)
AR (2) AR012998A1 (en:Method)
AT (1) ATE355840T1 (en:Method)
AU (1) AU8539398A (en:Method)
BG (2) BG109398A (en:Method)
BR (1) BR9810172A (en:Method)
CA (1) CA2294582C (en:Method)
CY (2) CY1107643T1 (en:Method)
CZ (1) CZ298469B6 (en:Method)
DE (2) DE69837261T2 (en:Method)
DK (1) DK0996444T3 (en:Method)
DZ (1) DZ2520A1 (en:Method)
EA (1) EA003144B1 (en:Method)
ES (1) ES2284212T3 (en:Method)
ID (1) ID23372A (en:Method)
IL (3) IL133142A0 (en:Method)
IN (1) IN189722B (en:Method)
LU (1) LU91356I2 (en:Method)
MA (1) MA26512A1 (en:Method)
MY (1) MY129897A (en:Method)
NL (1) NL300288I2 (en:Method)
NO (4) NO324993B1 (en:Method)
NZ (1) NZ501260A (en:Method)
OA (1) OA11516A (en:Method)
PE (1) PE83199A1 (en:Method)
PL (2) PL195140B1 (en:Method)
PT (1) PT996444E (en:Method)
SI (1) SI0996444T1 (en:Method)
SK (1) SK286029B6 (en:Method)
TR (1) TR199903057T2 (en:Method)
TW (1) TW565449B (en:Method)
UY (1) UY25049A1 (en:Method)
WO (1) WO1998057634A1 (en:Method)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ286920A (en) * 1995-07-03 1997-06-24 Sankyo Co Use of combination of hmg-coa reductase inhibitors and of insulin sensitizers for the prevention/treatment of arteriosclerosis or xanthoma
GB9712857D0 (en) * 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
PT974356E (pt) * 1998-07-15 2004-02-27 Merck Sante Sas Comprimidos compreendendo uma combinacao de metformina e de glibenclamida
AU3960400A (en) * 1999-03-05 2000-09-28 Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv
TWI249401B (en) 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
DE60037602T2 (de) 1999-04-23 2009-01-08 Smithkline Beecham P.L.C., Brentford Herstellung einer polymorphen Form eines Thiazolidindionderivates
NZ518278A (en) 1999-11-03 2004-10-29 Bristol Myers Squibb Co Pharmaceutical composition comprising a combination of metformin and glibenclamide
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
MY125516A (en) * 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
JP2003514011A (ja) * 1999-11-16 2003-04-15 スミスクライン ビーチャム パブリック リミテッド カンパニー チアゾリジンジオン−塩酸メトホルミンを含む医薬組成物
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
CA2407713A1 (en) * 2000-05-01 2001-11-08 Aeropharm Technology, Inc. A core formulation
FR2812547B1 (fr) * 2000-08-04 2002-10-31 Lipha Composition pharmaceutique comprenant une association metformine et derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
WO2002055009A1 (en) 2001-01-12 2002-07-18 Sun Pharmaceutical Industries Limited Spaced drug delivery system
FR2838968A1 (fr) * 2002-04-30 2003-10-31 Lipha Association d'insuline et d'un derive de thiazolidinedione et son utilisation pour traiter le diabete
AU2002356419A1 (en) 2002-06-17 2003-12-31 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
CA2499597C (en) * 2002-09-20 2012-01-17 Unchalee Kositprapa Multistage formulation containing a biguanide and thiazolidindione derivatives
UA80991C2 (en) * 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
KR101114808B1 (ko) 2003-01-29 2012-02-15 다케다 야쿠힌 고교 가부시키가이샤 피복 제제의 제조법
EP1738754B1 (en) 2004-04-14 2015-07-15 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
CN1327840C (zh) * 2004-06-08 2007-07-25 天津药物研究院 一种药物组合物及其在制备用于治疗糖尿病中的应用
WO2006011397A1 (ja) * 2004-07-27 2006-02-02 Kowa Company., Ltd. 糖尿病の予防または治療のための薬剤
WO2006086727A2 (en) * 2005-02-09 2006-08-17 Entelos, Inc. Treating diabetes with glucagon-like peptide-1 secretagogues
JPWO2007007757A1 (ja) * 2005-07-12 2009-01-29 第一三共株式会社 ＰＰＡＲγアゴニストを含有する医薬組成物
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
DE06252444T8 (de) * 2006-05-09 2009-03-19 Teva Pharmaceutical Industries Ltd. 2-N-{5-[[4-[2-(Methyl-2-pyridinylamino)-ethoxy]-phenyl]-methyl]-2,4-thiazolidindion}-bernsteinsäure, Verfahren zur Herstellung und Zusammensetzungen mit Rosiglitazonmaleat
CN101069745B (zh) * 2006-05-12 2010-07-21 北京华安佛医药研究中心有限公司 治疗2型糖尿病的药物组合物
US7919410B2 (en) * 2007-03-14 2011-04-05 Aptina Imaging Corporation Packaging methods for imager devices
EP2313360B1 (en) * 2008-07-28 2012-09-05 Syddansk Universitet Compounds for the treatment of metabolic diseases
DE102009053562A1 (de) 2009-11-18 2011-05-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Rosiglitazonsuccinat enthaltende pharmazeutische Zusammensetzung
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
CA2823397C (en) 2011-01-07 2020-03-10 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
CN104254325A (zh) 2012-01-06 2014-12-31 埃尔舍利克斯治疗公司 双胍组合物和治疗代谢性病症的方法
MX379226B (es) 2012-01-06 2025-03-11 Anji Pharma Us Llc Composiciones y métodos para tratar trastornos metabólicos.

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
DE3856378T2 (de) * 1987-09-04 2000-05-11 Beecham Group P.L.C., Brentford Substituierte Thiazolidindionderivate
US4895862A (en) * 1989-04-21 1990-01-23 American Home Products Corp. Novel benzyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
US5068342A (en) * 1989-10-27 1991-11-26 American Home Products Corporation 5-[(1- and 2-naphthalenyl)thio and sulfonyl]-2,4-thiazolidinediones and derivatives thereof
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
JPH04210683A (ja) * 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
DE69219136T2 (de) * 1991-08-26 1997-08-28 Pharmacia & Upjohn Co., Kalamazoo, Mich. Flüssiges nahrungsmittel, das 3-guanidinopropionsäure enthält
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
EP0832066B1 (en) * 1995-06-06 2001-09-12 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
JPH09270635A (ja) * 1996-04-01 1997-10-14 Honda Motor Co Ltd 平面アンテナモジュール
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US20020177612A1 (en) * 1997-06-05 2002-11-28 Smithkline Beecham P.I.C. Composition comprising 5-[4-[2-(N-methyl-N-2-pyridy)amino)ethoxy]benzyl]thiazolidine-2,4-dione
US20020016287A1 (en) * 1997-07-18 2002-02-07 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
ATE261935T1 (de) * 1997-12-08 2004-04-15 Bristol Myers Squibb Co Neue metformin salze und verfahren
EP1555845A1 (de) * 2004-01-15 2005-07-20 Siemens Aktiengesellschaft Verfahren zur Positionsbestimmung von Teilnehmerstationen eines Funkkommunikationssystems

Also Published As

Publication number Publication date
US20080090881A1 (en) 2008-04-17
NO20063000L (no) 1999-12-17
MA26512A1 (fr) 2004-12-20
AP1279A (en) 2004-05-20
EP1787646A3 (en) 2007-10-03
EA003144B1 (ru) 2003-02-27
PL195136B1 (pl) 2007-08-31
IL133142A0 (en) 2001-03-19
SK286029B6 (sk) 2008-01-07
AR012998A1 (es) 2000-11-22
BG104060A (en) 2000-10-31
IN189722B (en:Method) 2003-04-19
AR012995A1 (es) 2000-11-22
BG109398A (bg) 2006-05-31
DZ2520A1 (fr) 2003-02-01
WO1998057634A1 (en) 1998-12-23
LU91356I2 (fr) 2008-01-29
NO20090846L (no) 1999-12-17
JP2002504137A (ja) 2002-02-05
CA2294582A1 (en) 1998-12-23
NL300288I2 (nl) 2009-06-02
US20060100247A1 (en) 2006-05-11
NO326958B1 (no) 2009-03-23
NO2008003I1 (no) 2008-04-21
KR20010013844A (ko) 2001-02-26
CN1114404C (zh) 2003-07-16
ES2284212T3 (es) 2007-11-01
PL337362A1 (en) 2000-08-14
UY25049A1 (es) 2000-09-29
AP9901719A0 (en) 1999-12-31
PL195140B1 (pl) 2007-08-31
BR9810172A (pt) 2000-08-08
KR100666591B1 (ko) 2007-01-11
ATE355840T1 (de) 2007-03-15
BG64818B1 (bg) 2006-05-31
CY1107643T1 (el) 2012-01-25
SI0996444T1 (sl) 2007-08-31
CZ9904578A3 (en) 2001-06-13
CA2294582C (en) 2008-02-12
NO2008003I2 (no) 2010-06-28
CN1230171C (zh) 2005-12-07
DE69837261D1 (de) 2007-04-19
OA11516A (en) 2004-02-04
MY129897A (en) 2007-05-31
EA200000041A1 (ru) 2000-08-28
CN1260716A (zh) 2000-07-19
EP1787646A2 (en) 2007-05-23
CN1429551A (zh) 2003-07-16
EP0996444A1 (en) 2000-05-03
NO324993B1 (no) 2008-01-14
AU8539398A (en) 1999-01-04
ID23372A (id) 2000-04-20
HK1028193A1 (en) 2001-02-09
NL300288I1 (nl) 2007-11-01
CY2007018I1 (el) 2012-01-25
DK0996444T3 (da) 2007-07-02
SK179299A3 (en) 2000-11-07
NZ501260A (en) 2002-09-27
PT996444E (pt) 2007-06-08
NO996266L (no) 1999-12-17
PE83199A1 (es) 1999-10-22
EP0996444B1 (en) 2007-03-07
US20070004780A1 (en) 2007-01-04
DE122007000054I1 (de) 2007-12-13
IL173650A0 (en) 2006-07-05
DE69837261T2 (de) 2007-11-08
KR20060105005A (ko) 2006-10-09
TW565449B (en) 2003-12-11
IL133142A (en) 2006-06-11
CZ298469B6 (cs) 2007-10-10
NO996266D0 (no) 1999-12-17

Similar Documents

Publication Publication Date Title
TR199903057T2 (xx) Diabetin tiazolidinedion ve metformin ile tedavisi.
MXPA02012763A (es) Combinaciones de inhibidores de dipeptidil peptidasa iv y otros agentes antidiabeticos para el tratamiento de diabetes mellitus.
UY25799A1 (es) Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina y otro agente antidiabético.
MY155219A (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and biguanide
TR199903095T2 (xx) Diabetin roziglitazon ve ins�lin ile tedavisi.
TR199903072T2 (xx) Diabetin tiazolidinedion ve alfa-glukosidaz ile tedavisi.
AP2000001735A0 (en) Treatment of diabetes with thiazolidinedione insulin secretagogue and alpha glucocidase inhibitor.
TR200101336T2 (tr) Bir-beta-agonisti ile başka bir antidiyabetik madde içeren kombinasyonlar
MY138246A (en) Treatment of diabetes with thiazolidione and sulphonylurea.
TR199903096T2 (xx) Diabetin tiazolidinedion ve s�lfonil�re ile tedavisi.
ECSP982591A (es) Nuevo metodo de tratamiento iv
TR200000957T2 (tr) Hiperglisemi tedavisinde tiazolidinedion kullanımı
ECSP982535A (es) Nuevo metodo de tratamiento (i)
ECSP982542A (es) Nuevo metodo de tratamiento iii